
Inhibikase Therapeutics, Inc.: updates and filings
Price
$1.32
November 20, 2026Market cap $260M
What Ploutos Investor adds for Inhibikase Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 10, 2026next Feb 11, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
November 2026
August 2026
July 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 10, 2026Results of operationsForm8-K
- Oct 20, 2026Officer or director change, Regulation FD disclosureForm8-K
- Sep 8, 2026Regulation FD disclosureForm8-K
- Aug 26, 2026Change of auditorForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 11, 2026Shares registered for employeesFormS-8
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 11, 2026Results of operationsForm8-K
- Jul 31, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 29, 2026Unregistered sale of sharesForm8-K
- Jul 28, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 23, 2026Regulation FD disclosureForm8-K
- Jul 17, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 14, 2026Other material eventsForm8-K
- Jun 29, 2026Officer or director change, amended articles or bylaws, shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 12, 2026Results of operationsForm8-K
- Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 10, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 10, 2026 | 8-K | Results of operations | Document |
| Oct 20, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Sep 8, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 26, 2026 | 8-K | Change of auditor | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 11, 2026 | S-8 | Shares registered for employees | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 11, 2026 | 8-K | Results of operations | Document |
| Jul 31, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 29, 2026 | 8-K | Unregistered sale of shares | Document |
| Jul 28, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 23, 2026 | 8-K | Regulation FD disclosure | Document |
| Jul 17, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 14, 2026 | 8-K | Other material events | Document |
| Jun 29, 2026 | 8-K | Officer or director change, amended articles or bylaws, shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 12, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 31, 2018.
The full analysis
What do Inhibikase Therapeutics's filings show?
The filings are where every one of Inhibikase Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.